Industry News

Ignyta Inc, a biotechnology company focused on precision medicine in oncology, announced on Tuesday that it has appointed Dr Christian V. Kuhlen as its general counsel and secretary, replacing Matt Onaitis. Since 2007, Dr Kuhlen has served as general counsel, vice president and secretary of Genoptix Inc, where he led the legal and corporate governance functions from its initial public offering in 2007, through its successful acquisition by Novartis in 2011.."/>
Ignyta names Dr Christian V. Kuhlen as General Counsel and Secretary
Fennec Pharmaceuticals, Inc., today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New York City. The Fennec presentation will be webcast live and can be accessed at http://wsw.com/webcast/cantor4/frx. to or by visiting the investor section of the Company's..."/>
Fennec to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference in New York on July 13, 2016
Mazor Robotics Ltd., a developer of innovative guidance systems and complementary products, announced today that it received orders for eleven Renaissance systems in the second quarter ended June 30, 2016. The Company received orders for six systems in the U.S., including two systems with the brain module. Internationally, the Company received purchase orders for five systems from its distribution partners, including three systems in China, one in Italy and..."/>
Mazor Robotics Receives Eleven Renaissance Systems Orders During the Second Quarter of 2016
Aurobindo Pharma eyes Teva's over $1 billion European assets. Aurobindo Pharma Ltd, India's fourth-largest drug maker, is considering joining the race to buy assets of over $1 billion from Teva Pharmaceutical Industries Ltd that are being divested by the Israel-based company in the UK, Ireland and Iceland as a precondition to Teva's acquisition of Allergan Plc.' s generic..."/>
Deals Buzz: Aurobindo joins fray to buy Teva's assets; Practo in talks to raise $50-60 mn [Mint, New Delhi]
Valeant Pharmaceuticals International, Inc.' s wholly owned subsidiary, Bausch+ Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology. LBN 0.024% is an intraocular pressure lowering single-agent eye drop dosed once daily for patients with open angle..."/>
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
Valeant Pharmaceuticals International, Inc.' s wholly owned subsidiary, Bausch+ Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology. LBN 0.024% is an intraocular..."/>
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
Valeant Pharmaceuticals International, Inc.' s wholly owned subsidiary, Bausch+ Lomb, a leading global eye health company, and Nicox S.A. today announced that the results of a Phase 3 study for latanoprostene bunod ophthalmic solution 0.024% have been published in the American Journal of Ophthalmology. LBN 0.024% is an intraocular..."/>
Bausch + Lomb and Nicox Announce the Publication of Latanoprostene Bunod Ophthalmic Solution 0.024% Phase 3 Study Results in American Journal of Ophthalmology
American Renal Associates. The insurer says the company used "deception and unlawful means" in persuading patients with end-stage..."/>
Health insurer accuses dialysis provider of deceptive scheme to inflate bills [Sun Sentinel]
Abbott Laboratories has a new trick up its sleeve: the disappearing heart stent. Food and Drug Administration has approved the company's Absorb stent that is designed to dissolve after treating a blocked blood vessel, Abbott said Tuesday. The technology is the first of its kind in the U.S."/>
New Abbott stent, which dissolves in blood vessel, gets FDA approval [Chicago Tribune]
Danaher Corp. completed its spinoff of its older, industrial businesses over the weekend. In the process, Tektronix became part of a new company: Fortive, based in Everett, Washington."/>
Fortive spinoff complete, Tektronix has new owner [The Oregonian, Portland, Ore.]
HealthSouth Corp. are partnering to build a $12.2 million, 35- bed rehabilitation hospital on the third floor of BJC's Barnes-Jewish St. Louis-based nonprofit health system, said Tuesday it filed a certificate of need with the state of Missouri for the hospital slated to open in summer 2017 after a nine-month construction process. The 39,000- square-foot hospital, which will add 86 jobs in its first year, will serve as a satellite location of existing..."/>
BJC, HealthSouth to build $12.2 million rehab hospital in St. Peters [St. Louis Post-Dispatch]
Luminex Corp. has closed its acquisition of US-based molecular microbiology and molecular diagnostic firm Nanosphere, Inc. forUSD 1.35 per share in an all cash transaction valued at approximatelyUSD 58 m, the company said. Nanosphere offers proprietary diagnostic tools that enable rapid and accurate detection of respiratory, gastroenteric and bloodstream infections. Luminex said that Nanosphere's Verigene platform, broad..."/>
Luminex Closes USD 58m Acquisition of Molecular Diagnostics Firm Nanosphere
AmSurg Corp. physician services division Sheridan has acquired US-based radiology services provider AllegiantMD, Inc. and certain affiliated entities, the company said. AllegiantMD will join Sheridan's existing roster of over 300 fellowship trained, board certified radiologists, who cover 150 facilities across 22 states. Sheridan radiologists cover all subspecialty designations with 100%..."/>
AmSurg's Physician Services Division Sheridan Acquires US Radiology Specialist AllegiantMD
Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference, issued 05- Jul-2016 by Trovagene, Inc. over PR Newswire, we are advised by the company that the second paragraph, first sentence, should read "Trovagene is scheduled to present on Wednesday, July 13, 2016 at 1:30 pm EDT." rather than "Trovagene is scheduled to present on Wednesday, July 13, 2016 at 3:30 pm EDT. The complete, corrected release follows:."/>
/C O R R E C T I O N -- Trovagene, Inc./
BioCryst Pharmaceuticals has received an additional $5.5 million in federal funding to further develop BCX4430, its experimental drug for treating Ebola and other viral infections. With the latest funding from the National Institute of Allergy and Infectious Diseases, announced Tuesday, BioCryst's total federal funding could go as high as $39.5 million if all contract options are exercised. "The additional support from NIAID emphasizes the..."/>
BRIEF: BioCryst Pharmaceuticals lands $5.5 million in federal funding [The News & Observer (Raleigh, N.C.)]
Propanc Health Group Corporation, an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company executed a Letter Agreement with an institutional investor resulting in the Company receiving $314,286 in order to progress their lead product, PRP, towards first-in-man..."/>
Propanc Receives Investment to Initiate GLP Safety Toxicology Study for PRP
BioCryst Pharmaceuticals has received an additional $5.5 million in funding to develop its potential hemorrhagic fever virus treatment, called BCX4430. The funding was added to the $35.4 million already awarded through a contract with the National Institute of Allergy and Infectious Diseases, which is intended to advance the Phase 1 clinical program for the antiviral. The overall contract amount that NIAID can award to BioCryst could reach $39.5 million, if..."/>
BioCryst receives $5.5M in NIAID funding for potential Ebola treatment [The Herald-Sun, Durham, N.C.]
Ensign Group, Inc., the parent company of the Ensign™ group of skilled nursing, rehabilitative care services, home healthcare, hospice care, assisted living and urgent care companies, announced today that it acquired the operations and real estate of Riverbend Post Acute Rehabilitation, a 161- bed skilled nursing and 10- bed assisted living facility in Kansas City, Kansas. The acquisition was effective July 1, 2016, and included the..."/>
The Ensign Group Acquires Kansas Skilled Nursing Facility
Theratechnologies Inc. today announced its financial results for the second quarter ended May 31, 2016.. Second quarter 2016 financial highlights. --Net sales of $9,026,000-- Adjusted EBITDA of $1,362,000-- Net loss of $498,000 or 0.01 per share-- Liquidities of $9,239,000."/>
Theratechnologies Announces Financial Results for Second Quarter of 2016
Thermo Fisher Scientific Inc., the world leader in serving science, announced that it will release its financial results for the second quarter 2016 before the market opens on Thursday, July 28, 2016, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its second quarter financial performance, as well as future expectations. To listen, call 201-0168 within the U.S. or 788-4901 outside the U.S."/>
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2016

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials655 Articles
Consumer Discretionary599 Articles
Information Technology578 Articles
Industrials440 Articles
Health Care385 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.